Feng Zhang

Feng Zhang
PuppyEggs · CC BY-SA 4.0 · source
Name	Feng Zhang
Birth date	1981
Fields	Molecular biology; Neuroscience; Genetics; Bioengineering
Workplaces	McGovern Institute for Brain Research; Broad Institute; Massachusetts Institute of Technology; Howard Hughes Medical Institute
Alma mater	Boston University; Harvard University; Massachusetts Institute of Technology
Known for	CRISPR gene editing; optogenetics; base editing
Awards	NIH Director's Pioneer Award; Smithsonian Magazine Innovator of the Year; Keio Medical Science Prize

Feng Zhang Feng Zhang is an American molecular biologist and neuroscientist known for pioneering work in genome engineering, optogenetics, and development of CRISPR-based tools. He is a core member of the Broad Institute, a professor at Massachusetts Institute of Technology, and an investigator at the Howard Hughes Medical Institute. Zhang's work bridges basic research in neuroscience with translational efforts in genetics and biotechnology.

Early life and education

Zhang grew up in the United States after immigrating from China, attending primary and secondary schools before enrolling at Boston University for undergraduate studies in biology and mathematics. He completed graduate training at Harvard University in the laboratories connected to the Harvard-MIT Division of Health Sciences and Technology and conducted postdoctoral research at institutions associated with the emergence of modern optogenetics, including collaborations with groups at Stanford University and the Massachusetts Institute of Technology.

Research and career

Zhang joined the Broad Institute as a core institute member and established a laboratory at MIT and the McGovern Institute for Brain Research focused on molecular tools for neuroscience and genome engineering. His laboratory has developed technologies intersecting neuroscience techniques like optogenetics pioneered by groups at University of California, Berkeley and genome-editing platforms stemming from foundational work at University of California, Berkeley and University of Vienna. Zhang has held appointments with the Howard Hughes Medical Institute and has collaborated with investigators at the Whitehead Institute, Harvard Medical School, and industrial partners in the biotechnology sector, contributing to high-throughput genetic screening and functional genomics initiatives.

CRISPR and gene-editing contributions

Zhang was among the first researchers to adapt bacterial adaptive immune systems for mammalian genome editing, translating discoveries about CRISPR-associated proteins from groups at University of Alicante and University of Freiburg into broadly usable tools. His team reported protocols for programmable nucleases, expanding applications first reported by investigators at University of California, Berkeley and researchers associated with Harvard University. Subsequent work in Zhang's laboratory included development of smaller and programmable CRISPR variants, base-editing approaches related to efforts by groups at Broad Institute collaborators, and methods for delivery and specificity improvements that have been implemented in preclinical studies at centers such as Massachusetts General Hospital and collaborative initiatives with pharmaceutical companies including Editas Medicine and other biotechnology firms.

Patents, legal disputes, and commercialization

The translation of CRISPR technologies led to multiple patent filings and licensing discussions involving the Broad Institute, University of California, and associated entities such as The Regents of the University of California and corporate licensees. High-profile inter-institutional disputes over patent priority involved legal proceedings at bodies like the United States Patent and Trademark Office and garnered participation from legal teams representing the Broad Institute and University of California, Berkeley. Zhang has been associated with startup formation and technology transfer activities, collaborating with companies spun out to commercialize genome-editing therapeutics and research tools in partnerships with venture capital firms and biotech incubators.

Awards and honors

Zhang's contributions have been recognized by awards and honors from institutions including the National Institutes of Health, scientific societies, and philanthropic foundations. Notable recognitions include prizes and fellowships conferred by organizations such as the Keio University and listings in science and technology media outlets that have profiled leading innovators. He has been elected to professional organizations and invited to deliver keynote lectures at conferences organized by groups like the Cold Spring Harbor Laboratory and the American Association for the Advancement of Science.

Personal life and outreach

Zhang maintains academic collaborations across universities and engages in outreach related to ethical, regulatory, and societal implications of genome editing with stakeholders including policy groups at National Academy of Sciences, patient advocacy organizations, and industry consortia. He has taken part in public discussions, scientific advisory roles, and educational initiatives in partnership with institutions such as Harvard Medical School and community science programs.

Category:American molecular biologists Category:Genome editing